Marcia Belvin, SVP and Chief Scientific Officer at CytomX Therapeutics ($CTMX), sold shares on the open market twice in the last year for a total of about $49,000. Her most recent sale occurred on June 16, 2025. These sales rank 10,417th among 11,678 insiders, compared to an average sale value of $8.6 million across 6.37 transactions per insider. Belvin made no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 17, 2026 | CytomX Therapeutics, Inc. | $CTMX | BELVIN MARCIA | SVP, Chief Scientific Officer | S | Common Stock | 31492 | $6.42 | 300,760.0000 | 169,435,395 | 9.48% | 0.02% |
| Feb. 2, 2026 | CytomX Therapeutics, Inc. | $CTMX | BELVIN MARCIA | SVP, Chief Scientific Officer | A | Stock Option (Right to Buy) | 250000 | $0.00 | 250,000.0000 | 169,435,395 | 9999.99% | 0.15% |
| Feb. 2, 2026 | CytomX Therapeutics, Inc. | $CTMX | BELVIN MARCIA | SVP, Chief Scientific Officer | A | Common Stock | 60000 | $0.00 | 332,252.0000 | 169,435,395 | 22.04% | 0.04% |
| Sept. 26, 2025 | CytomX Therapeutics, Inc. | $CTMX | BELVIN MARCIA | SVP, Chief Scientific Officer | A | Stock Option (Right to Buy) | 36300 | $0.00 | 36,300.0000 | 80,099,889 | 9999.99% | 0.05% |
| Sept. 26, 2025 | CytomX Therapeutics, Inc. | $CTMX | BELVIN MARCIA | SVP, Chief Scientific Officer | A | Performance Stock Units (PSUs) | 18150 | $0.00 | 18,150.0000 | 80,099,889 | 9999.99% | 0.02% |
| June 13, 2025 | CytomX Therapeutics, Inc. | $CTMX | BELVIN MARCIA | SVP, Chief Scientific Officer | M | Performance Stock Units | 37500 | $0.00 | 0.0000 | 80,099,889 | 100.00% | 0.05% |
| June 16, 2025 | CytomX Therapeutics, Inc. | $CTMX | BELVIN MARCIA | SVP, Chief Scientific Officer | S | Common Stock | 13884 | $2.69 | 272,252.0000 | 80,099,889 | 4.85% | 0.02% |
| June 13, 2025 | CytomX Therapeutics, Inc. | $CTMX | BELVIN MARCIA | SVP, Chief Scientific Officer | M | Common Stock | 37500 | $0.00 | 286,136.0000 | 80,099,889 | 15.08% | 0.05% |
| March 18, 2025 | CytomX Therapeutics, Inc. | $CTMX | BELVIN MARCIA | SVP, Chief Scientific Officer | S | Common Stock | 19512 | $0.60 | 248,636.0000 | 80,099,889 | 7.28% | 0.02% |
| Feb. 4, 2025 | CytomX Therapeutics, Inc. | $CTMX | BELVIN MARCIA | SVP, Chief Scientific Officer | A | Common Stock | 35000 | $0.00 | 210,648.0000 | 0 | 19.93% | 0.00% |
| Feb. 4, 2025 | CytomX Therapeutics, Inc. | $CTMX | BELVIN MARCIA | SVP, Chief Scientific Officer | A | Stock Option (Right to Buy) | 150000 | $0.00 | 150,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 4, 2025 | CytomX Therapeutics, Inc. | $CTMX | BELVIN MARCIA | SVP, Chief Scientific Officer | A | Stock Option (Right to Buy) | 115000 | $0.00 | 115,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 4, 2025 | CytomX Therapeutics, Inc. | $CTMX | BELVIN MARCIA | SVP, Chief Scientific Officer | A | Common Stock | 57500 | $0.00 | 268,148.0000 | 0 | 27.30% | 0.00% |
| Feb. 4, 2025 | CytomX Therapeutics, Inc. | $CTMX | BELVIN MARCIA | SVP, Chief Scientific Officer | A | Stock Option (Right to Buy) | 115000 | $0.00 | 115,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 4, 2025 | CytomX Therapeutics, Inc. | $CTMX | BELVIN MARCIA | SVP, Chief Scientific Officer | A | Common Stock | 30000 | $0.00 | 205,648.0000 | 0 | 17.08% | 0.00% |
| Feb. 4, 2025 | CytomX Therapeutics, Inc. | $CTMX | BELVIN MARCIA | SVP, Chief Scientific Officer | A | Common Stock | 57500 | $0.00 | 263,148.0000 | 0 | 27.96% | 0.00% |
| Feb. 4, 2025 | CytomX Therapeutics, Inc. | $CTMX | BELVIN MARCIA | SVP, Chief Scientific Officer | A | Stock Option (Right to Buy) | 140000 | $0.00 | 140,000.0000 | 0 | 9999.99% | 0.00% |
| Aug. 20, 2024 | CytomX Therapeutics, Inc. | $CTMX | BELVIN MARCIA | SVP, Chief Scientific Officer | M | Common Stock | 11250 | $0.00 | 179,829.0000 | 0 | 6.67% | 0.00% |
| Aug. 20, 2024 | CytomX Therapeutics, Inc. | $CTMX | BELVIN MARCIA | SVP, Chief Scientific Officer | M | Performance Stock Units (PSUs) | 11250 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Aug. 20, 2024 | CytomX Therapeutics, Inc. | $CTMX | BELVIN MARCIA | SVP, Chief Scientific Officer | S | Common Stock | 4181 | $1.23 | 175,648.0000 | 0 | 2.32% | 0.00% |
| March 19, 2024 | CytomX Therapeutics, Inc. | $CTMX | BELVIN MARCIA | SVP, Chief Scientific Officer | S | Common Stock | 12795 | $2.09 | 168,579.0000 | 0 | 7.05% | 0.00% |
| Jan. 18, 2024 | CytomX Therapeutics, Inc. | $CTMX | BELVIN MARCIA | SVP, Chief Scientific Officer | A | Performance Stock Units (PSUs) | 75000 | $0.00 | 75,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 18, 2024 | CytomX Therapeutics, Inc. | $CTMX | BELVIN MARCIA | SVP, Chief Scientific Officer | A | Stock Option (Right to Buy) | 122500 | $0.00 | 122,500.0000 | 0 | 9999.99% | 0.00% |
| Jan. 18, 2024 | CytomX Therapeutics, Inc. | $CTMX | BELVIN MARCIA | SVP, Chief Scientific Officer | A | Common Stock | 26250 | $0.00 | 181,374.0000 | 0 | 16.92% | 0.00% |